Oblimersen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Oblimersen
DrugBank Accession Number
DB13811
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Synonyms
  • Oblimersen

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbroxolThe risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Bupivacaine.
Food Interactions
Not Available

Categories

ATC Codes
L01XX36 — Oblimersen
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
85J5ZP6YSL
CAS number
190977-41-4
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
Wikipedia
Oblimersen

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
3CompletedTreatmentMelanoma1somestatusstop reasonjust information to hide
2TerminatedTreatmentMelanoma1somestatusstop reasonjust information to hide
2, 3TerminatedTreatmentAdvanced Melanoma and Normal or Impaired / Hepatic Function1somestatusstop reasonjust information to hide
1CompletedHealth Services ResearchMildly Impaired Renal Function / Moderately Impaired Renal Function / Normal Renal Function1somestatusstop reasonjust information to hide
1CompletedTreatmentSolid Tumors1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54